ClinicalTrials.govpublic full text
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 830616
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.